Loading
Laboratorio Farmaceutico Erfo Stock: price and insider trades · Italy
No insider purchase over the last 90 days. The latest was filed 07 Jun 2026.
Laboratorio Farmaceutico Erfo: what insiders have been doing
Every trade that managers of Laboratorio Farmaceutico Erfo disclose to Consob is tracked on this page. The company sits in the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Laboratorio Farmaceutico Erfo logged 7 filings by 3 insiders.
On the market, 1 insider bought (3 purchases totalling €29k) while 1 insider sold (1 sale totalling €499k). The net balance comes to €470k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 chief executive. One trade stands out by size: a sale of €499k, disclosed on 16 December 2025, or 5.3% of market capitalisation.
The clock since the last published purchase (7 June 2026) now reads 132 days. Filings reach the Consob feed a median of 1 day after the trade. The legal deadline for notifying a trade is three business days (MAR article 19).
Across the 224 companies tracked on its exchange, the median is 3 filings; at 7 filings, this issuer sits above that mark. Over the whole record (from 2024), the tally stands at 3 purchases and 3 sales.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from Consob disclosures alone and does not predict where the share price will go.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€28,640
3 ops. · all time
Sell Volume
€515,940
3 ops. · all time
Who traded when
BuySaleAnonymous (PDMR)3 buys
Unknown2 sales
Marco Campagnano1 sale
Since the insiders bought
- Anonymous (PDMR)-3.7%Entry €1.10 · Close 16 Oct 2026 €1.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,240 of 24,158 companies
59.4
score / 100
Value53
Quality66
FCF yld-18%
Earn yld4.2%
EV/EBITDA5.2x
ROE8.7%
Gross mgn70%
Net mgn4.0%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€1.08
Analyst consensus
1 analysts€2.08Target €2.08(+93%)€2.08
Income statement
Revenue€9.7M
Gross profit€6.7M70% margin
EBITDA€2.0M21% margin
Net income€382k7.6% margin
Valuation
PER (trailing)21.6x
P/Book1.2x
Beta1.23
Balance sheet & cash
Market cap€9.2M
Total debt€1.3M
Free Cash Flow-€1.6M
Debt / Equity14%
Profitability & ownership
ROE8.7%
ROA5.6%
% insiders61.4%
% institutions0.0%
Last declaration on 29 July 2026
Declarations12 total
10,000 shares@ €1.1038.4% of flowShareISIN IT0005497885CONSOB:185448
Canonical exit: 3 Sept 2026 (T+90)
8,000 shares@ €1.1030.7% of flowShareISIN IT0005497885CONSOB:185248
Canonical exit: 31 Aug 2026 (T+90)
8,000 shares@ €1.10530.9% of flowShareISIN IT0005497885CONSOB:184926
Canonical exit: 23 Aug 2026 (T+90)
322,000 shares@ €1.555.33% mcap97.0% of flowShareISIN IT0005497885CONSOB:175561
1,000 shares@ €1.300.014% mcap100.0% of flowShareOTCISIN IT0005497885CONSOB:171451
11,000 shares@ €1.41270.17% mcap3.0% of flowShareOTCISIN IT0005497885CONSOB:169512
12 of 12 declarations
About Laboratorio Farmaceutico Erfo
Laboratorio Farmaceutico Erfo is a company focused on the development and manufacturing of pharmaceutical products. It operates in the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
